---
title: "Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse"
canonical: "https://www.renown.org/clinical-trials-directory/NCT04546399"
last_updated: "2026-10-09T23:12:55Z"
---

# Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

URL: https://www.renown.org/clinical-trials-directory/NCT04546399

Short Title: AALL1821

Enrollment Status: Recruiting

NCT #: [NCT04546399](https://clinicaltrials.gov/study/NCT04546399)

Specialty Area: Pediatric Hematology/Oncology

Condition Studied: CD19+ B-Cell Acute Lymphoblastic Leukemia

Age Groups: Child; Adult

Sex: All

Study Type: Interventional

Accepts Healthy Volunteers: No

Phase: II

Principal Investigator: Seema Rao, MD

Complete Study Details: https://clinicaltrials.gov/study/NCT04546399

## Study Information

### Summary / Purpose

This study looks at how well blinatumomab and nivolumab combined works compared to blinatumomab alone when given to children and young adults with first marrow relapse of B-ALL. Study doctors want to see if the combination of blinatumomab with nivolumab makes blinatumomab more effective.

### Who Can Participate

- Children and Adults 3 - 31 years of age
- Patients must have first relapse of CD19+ B-ALL
- Must have fully recovered from the acute toxic effects of all prior therapy
- Must have adequate renal, cardiac, and lung function

### What's Involved

- Assignment to a treatment group based on when and where the leukemia came back
- Random assignment to receive either blinatumomab alone or blinatumomab plus nivolumab
- Chemotherapy, which may include vincristine, dexamethasone, methotrexate, cytarabine, mercaptopurine, and asparaginase-type drugs (pegaspargase, calaspargase pegol, or pegcrisantaspase), depending on your treatment group
- Blinatumomab, an antibody that helps your immune system find and attack leukemia cells
- Nivolumab, a medicine that boosts the immune system, for participants assigned to that group
- Bone marrow aspiration and bone marrow biopsy to check how the leukemia is responding
- Lumbar puncture, a procedure that uses a needle to collect fluid from around the spinal cord
- Radiation therapy, if needed
- Sample collection for research

## Additional Information

Location: Renown Health, Office of Clinical Research

Address: 1500 E 2nd St. Reno, NV 89502

General Research: [775-982-3646](tel:775-982-3646)

Oncology Research: [775-982-5050](tel:775-982-5050)

Email: [Renown-CRD@renown.org](mailto:Renown-CRD@renown.org)
